-
Add to Cart The item has been addedAb183417-5mgAtinumab (anti-NOGO) (C007B-552918)
Price: $1,556.64List Price: $1,729.59Atinumab (anti-NOGO) is a monoclonal antibody targeting reticulon-4. It has immunomodulating activity and can be used for the research of spinal cord injury (SCI). -
Add to Cart The item has been addedrp173518-1mgB and T lymphocyte attenuator (C007B-434505)
Price: $2,729.10List Price: $3,032.34B and T lymphocyte attenuator. -
Add to Cart The item has been addedAb182793-100μgBimekizumab (anti-IL17A&IL-17F) (C007B-552703)
Price: $138.29List Price: $153.65Bimekizumab (anti-IL17A&:IL-17F) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. -
Add to Cart The item has been addedAb182793-10mgBimekizumab (anti-IL17A&IL-17F) (C007B-552704)
Price: $1,568.80List Price: $1,743.11Bimekizumab (anti-IL17A&:IL-17F) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. -
Add to Cart The item has been addedAb182793-1mgBimekizumab (anti-IL17A&IL-17F) (C007B-552705)
Price: $503.96List Price: $559.95Bimekizumab (anti-IL17A&:IL-17F) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. -
Add to Cart The item has been addedAb182793-5mgBimekizumab (anti-IL17A&IL-17F) (C007B-552706)
Price: $997.18List Price: $1,107.97Bimekizumab (anti-IL17A&:IL-17F) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. -
Add to Cart The item has been addedAb182918-100μgBotensilimab (anti-CTLA-4) (C007B-552779)
Price: $138.29List Price: $153.65Botensilimab (anti-CTLA4), a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator. Botensilimab (anti-CTLA4) can be used for the research of cancer. -
Add to Cart The item has been addedAb182918-10mgBotensilimab (anti-CTLA-4) (C007B-552780)
Price: $1,848.53List Price: $2,053.92Botensilimab (anti-CTLA4), a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator. Botensilimab (anti-CTLA4) can be used for the research of cancer. -
Add to Cart The item has been addedAb182918-5mgBotensilimab (anti-CTLA-4) (C007B-552782)
Price: $1,155.28List Price: $1,283.65Botensilimab (anti-CTLA4), a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator. Botensilimab (anti-CTLA4) can be used for the research of cancer. -
Add to Cart The item has been addedAb209915-100μgCantuzumab (anti-CanAg) (C007B-554250)
Price: $120.98List Price: $134.42Cantuzumab (anti-CanAg) is a monoclonal antibody that can binds the CanAg antigen. Cantuzumab (anti-CanAg) is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC). -
Add to Cart The item has been addedAb209915-10mgCantuzumab (anti-CanAg) (C007B-554251)
Price: $1,556.64List Price: $1,729.59Cantuzumab (anti-CanAg) is a monoclonal antibody that can binds the CanAg antigen. Cantuzumab (anti-CanAg) is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC). -
Add to Cart The item has been addedAb209915-1mgCantuzumab (anti-CanAg) (C007B-554252)
Price: $413.48List Price: $459.42Cantuzumab (anti-CanAg) is a monoclonal antibody that can binds the CanAg antigen. Cantuzumab (anti-CanAg) is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC).
